The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

which generally follows the CHMP's advice, is expected to make a final decision in the next one to two months. Eli Lilly previously won conditional European approval for Jaypirca in adults with ...

(RTTNews) - Eli Lilly and Company (LLY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca, a non-covalent ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

在医学界迎来了一则令人振奋的消息：全球领先的制药公司礼来宣布其研发的抗癌药物Jaypirca（吡托布鲁替尼）获得了欧洲药品管理局人用药品委员会（CHMP）的支持，该药物有望扩大用于治疗那些曾经接受过布鲁顿酪氨酸激酶抑制剂治疗后出现复发或对现有疗法反应不佳的慢性淋巴细胞白血病成人患者。这标志着在对抗这一顽固疾病方面取得了重要进展。

Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca ...

EastGroup Properties, Inc.  (the "Company", "we", "our", "us" or "EastGroup") announced today its recent business activity. As ...